Publications by authors named "Kazuhito Yamamoto"
Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs.
View Article and Find Full Text PDFVenetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival benefit and long-term outcomes with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azacitidine or placebo-azacitidine.
View Article and Find Full Text PDFArticle Synopsis
- A study found that combining anti-CD20 antibody with chemotherapy significantly improved overall survival in untreated advanced-stage follicular lymphoma (FL), but the best treatment approach remains uncertain.
- A long-term analysis of a clinical trial using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) showed a 15-year overall survival rate of 76.2% among 248 patients.
- The study reported no treatment-related deaths and low incidences of new malignancies, confirming that R-CHOP is both effective and safe as a first-line treatment for advanced FL over an extended follow-up period.
Article Synopsis
- - Epcoritamab, a bispecific antibody targeting CD3 and CD20, showed promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in a global phase II trial (EPCORE NHL-1), demonstrating deep and lasting responses with manageable side effects.
- - The phase I/II trial (EPCORE NHL-3) focused on Japanese patients with R/R CD20 B-cell non-Hodgkin's lymphoma who had received two or more prior treatments, revealing an overall response rate of 55.6% and a complete response rate of 44.4% at a median follow-up of 8.4 months after receiving subcutaneous epcoritamab.
Aim: The POLARIX trial showed that Pola + R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) prolongs progression-free survival (PFS) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), the conventional standard of care, with a similar safety profile. However, Pola + R-CHP has not been evaluated from the viewpoint of health economics in Japan. This study evaluates the cost-effectiveness of Pola + R-CHP for previously untreated DLBCL from a Japanese public healthcare payer's perspective.
View Article and Find Full Text PDFArticle Synopsis
- A subgroup analysis from the Asian phase II study of darinaparsin focused on its efficacy and safety in 37 Japanese patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
- The Japanese PTCL patients primarily had different histopathological types, with a median age of 70, and a high percentage having previously received various treatment regimens.
- The study found that the overall response rate for Japanese patients was 22.2%, similar to the 19.3% seen in the overall population, indicating that darinaparsin is a potentially effective and safe treatment for this specific group.
Progression-free survival after R-High CHOP/CHASER/LEED with auto-PBSCT in untreated mantle cell lymphoma in JCOG0406 study. A continuous pattern of relapse was observed.
View Article and Find Full Text PDFBackground: No consensus has been reached yet concerning treatment strategies for a sequential classic Hodgkin lymphoma (CHL) following gray zone lymphoma (GZL). Prognosis of GZL after a failed autologous hematopoietic stem-cell transplantation (auto-HCT) is poor and treatment strategy is very limited. As yet there are limited data showing clinical outcomes of brentuximab vedotin (BV) for GZL, especially for sequential CHL after GZL.
View Article and Find Full Text PDFArticle Synopsis
- A Phase 3 clinical trial (VIALE-C) showed that venetoclax combined with low-dose cytarabine improved outcomes for newly diagnosed acute myeloid leukemia patients who couldn't undergo intensive chemotherapy.
- Following the trial, an expanded access study in Japan provided this treatment to eligible patients, where they received the same dosages and precautions to prevent tumor lysis syndrome.
- Of the 14 patients enrolled, the most common serious side effect was neutropenia, and while some adverse events occurred, they were manageable, indicating that patient safety remains a priority despite potentially more severe cases in clinical practice.
Article Synopsis
- A multicenter study in Japan, HM-SCREEN-Japan 01, focused on detecting genetic mutations in acute myeloid leukemia (AML) patients using paraffin-embedded bone marrow clot samples, which is a less invasive method than using bone marrow fluid.* -
- The study involved 188 patients and found actionable genetic mutations in 38% of them, which could guide treatment decisions, while also detecting a high rate of genetic alterations and fusion transcripts.* -
- Key mutations, such as those in KIT and WT1, were linked to overall survival rates, highlighting the potential of comprehensive genomic profiling in identifying effective therapeutic targets for newly diagnosed and relapsed AML patients.*
Article Synopsis
- Adolescent and young adult cancer patients often face significant psychological distress and unmet needs that can be addressed with appropriate support tools like the Distress Thermometer and Problem List-Japanese version (DTPL-J).
- A recent study in Japan involving 361 participants found a high screening rate (90.3%) and a significant reduction in distress and supportive care needs one month after implementation of a psychosocial support program based on the DTPL-J.
- The program was deemed feasible and effective and has been continued in clinical routine across eight institutions as part of ongoing care for AYAs.
Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione, with antitumor activity and a mechanism of action markedly different from other available agents. This phase 2, nonrandomized, single-arm, open-label study evaluated the efficacy and safety of intravenous darinaparsin (300 mg/m2 over 1 hour, once daily for 5 consecutive days, per 21-day cycle) and its pharmacokinetics at multiple doses in 65 Asian patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The primary end point was the overall response rate (ORR).
View Article and Find Full Text PDFTirabrutinib is a Bruton's tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dose of 160 mg, 320 mg, or 480 mg once daily, or 300 mg twice daily (N = 3, 3, 4, and 7, respectively).
View Article and Find Full Text PDFPurpose: This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of bendamustine in patients with previously untreated indolent B-cell non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL) (Group 1) and patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) (Group 2).
Methods: Rituximab 375 mg/m was administered intravenously every 28 days to Group 1 patients on day 1 and every 21 days to Group 2 patients on day 1. Bendamustine 90 mg/m/day was administered to the former on days 1 and 2; bendamustine 120 mg/m/day was administered to the latter on days 2 and 3.
Article Synopsis
- * An internet survey conducted in 2016 with over 1,300 specialists revealed lower awareness of the term "AYA" among adult specialists, and differing opinions on the need for special wards for AYA patients based on age.
- * The findings highlighted a need for collaboration between pediatric and adult specialists to better support AYA patients, especially for those under 24, while also suggesting that care strategies should evolve based on the patient's age and history of treatment.
Article Synopsis
- - KIT is a receptor tyrosine kinase that, when mutated or overexpressed, can contribute to cancers like gastrointestinal stromal tumors and mast cell disease, leading to the development of targeted molecular therapies.
- - In acute myeloid leukemia (AML), genomic profiling reveals that mutations in several genes can influence patient prognosis, suggesting that personalized treatment based on genomic data could enhance outcomes.
- - The paper discusses previous research on mutations in AML, presents data from the HM-SCREEN-Japan-01 study involving unfit or relapsed AML patients, and explores new therapies targeting these mutations, such as tyrosine kinase inhibitors and heat shock protein 90 inhibitors.
Article Synopsis
- The Phase 3 trials Viale-A and Viale-C investigated the health-related quality of life (HRQoL) in patients with acute myeloid leukemia (AML) who were not suitable for intensive chemotherapy, focusing on treatments with venetoclax (VEN) combined with either azacitidine (AZA) or low-dose cytarabine (LDAC) versus placebo (PBO).
- Key patient-reported outcomes measured included global health status, physical functioning, cancer fatigue, and overall health status, with results indicating that patients receiving VEN had significantly longer time to deterioration (TTD) in multiple HRQoL metrics compared to those on placebo treatments.
- The findings suggest that ven
Article Synopsis
- There is no established prognostic model for patients with diffuse large B-cell lymphoma (DLBCL) undergoing intensive immunotherapy and autologous stem cell transplantation (ASCT), prompting the evaluation of the Kyoto Prognostic Index (KPI) as a potential new standard.
- In a study involving 58 patients from the JCOG0908 trial, researchers assessed the KPI's effectiveness in predicting overall survival (OS) and progression-free survival (PFS) compared to the traditional International Prognostic Index (IPI).
- Results indicated that the KPI provided higher 3-year OS and PFS rates across various risk groups compared to the IPI, suggesting that the KPI could be a more effective prognostic tool for high-risk DLB
Hematopoietic cell transplantation (HCT) represents a valuable therapeutic option for younger patients with mantle cell lymphoma (MCL). Despite the rarity of this disease, significant research efforts have been undertaken to improve the outcomes, and autologous HCT is currently considered an established treatment for younger patients who respond to induction therapy. The past 20 years have seen further progress by incorporating rituximab and high-dose cytarabine into induction therapy and adopting rituximab as posttransplant maintenance therapy.
View Article and Find Full Text PDFPurpose: There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10 in the VIALE-A trial.
Methods: The patients included in this report were treated with venetoclax and azacitidine.
Background: The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-azacitidine significantly prolonged overall survival compared with placebo-azacitidine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy. Herein, efficacy and safety of venetoclax-azacitidine are analyzed in the Japanese subgroup of VIALE-A patients.
Methods: Eligible Japanese patients were randomized 2:1 to venetoclax-azacitidine (N = 24) or placebo-azacitidine (N = 13).